Home Magazines Editors-in-Chief FAQs Contact Us

The use of generic medications in thalassemia and hemoglobinopathies: challenges, benefits, and economic impact


Thalassemia and hemoglobinopathies necessitate lifelong disease management, leading to significant treatment costs. Generic medications offer potential cost savings, but concerns persist regarding their comparative effectiveness and safety compared to brand-name drugs. This comprehensive review evaluates the evidence concerning the utilization of generics for transfusion-dependent thalassemia and hemoglobinopathies. Quality-assured generics can offer substantial cost savings for both health systems and patients, contingent upon ensuring bioequivalence, efficacy, pharmacovigilance, and addressing stakeholder concerns.